stockrow
Saturday 7 November 2026
Export BYSI’s income statement to Excel — free account
BeyondSpring Inc.
BYSI Healthcare Biotechnology
BeyondSpring Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.4 million.
- EPS
- +50.0%
- Free cash flow
- +35.8%
Quarter to June 2026, against a year earlier
0.61
0.02
−3.17%
Follow BYSI
Alert me
BeyondSpring Inc. (BYSI) P/E ratio
BeyondSpring Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2021 | 0.0× | — |
| Sep 2021 | 0.0× | — |
| Jun 2021 | 0.0× | — |
| Mar 2021 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACET Adicet Bio, Inc. compare | n/m |
| ALGS Aligos Therapeutics, Inc. compare | n/m |
| ABVC ABVC BioPharma, Inc. compare | n/m |
| AARD Aardvark Therapeutics, Inc. compare | n/m |
| MGX Metagenomi Therapeutics, Inc. compare | n/m |
| BYSI BeyondSpring Inc. | n/m |
| RNAZ TransCode Therapeutics Inc. compare | n/m |
| CVM Cel-Sci Corporation compare | n/m |
| PLRZ Polyrizon Ltd. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)